Home › B-Cell Lymphoma
B-Cell Lymphoma clinical trials recruiting in the U.S.
67 studies for B-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY19 studies
- Houston, TX16 studies
- Chicago, IL12 studies
- Philadelphia, PA11 studies
- Nashville, TN11 studies
- Rochester, MN10 studies
- Milwaukee, WI9 studies
- Baldwin Park, CA9 studies
- Cleveland, OH8 studies
- Boston, MA8 studies
- Charlotte, NC7 studies
- Columbus, OH7 studies
- Pittsburgh, PA7 studies
- Denver, CO7 studies
- Seattle, WA7 studies
- Washington, DC7 studies
- Dallas, TX7 studies
- Salt Lake City, UT7 studies
- Aurora, CO6 studies
- Edison, NJ6 studies
- New Haven, CT6 studies
- San Antonio, TX6 studies
- Los Angeles, CA6 studies
- St. Louis, MO5 studies
- Omaha, NE5 studies
- Atlanta, GA5 studies
- Mountain View, CA5 studies
- Kansas City, MO5 studies
- Ann Arbor, MI5 studies
- Cincinnati, OH4 studies
- Miami, FL4 studies
- Portland, OR4 studies
- Tampa, FL4 studies
- Jacksonville, FL4 studies
- Richmond, VA4 studies
- Winston-Salem, NC4 studies
- Indianapolis, IN4 studies
- Louisville, KY4 studies
- Cedar Rapids, IA4 studies
- Charlottesville, VA3 studies
By state
- Arizona5 studies
- California20 studies
- Colorado11 studies
- Connecticut6 studies
- District of Columbia3 studies
- Florida15 studies
- Georgia7 studies
- Illinois12 studies
- Indiana5 studies
- Iowa6 studies
- Kansas9 studies
- Kentucky4 studies
- Maryland7 studies
- Massachusetts8 studies
- Michigan7 studies
- Minnesota12 studies
- Missouri5 studies
- Nebraska5 studies
- New Jersey9 studies
- New York21 studies
- North Carolina11 studies
- Ohio16 studies
- Oregon5 studies
- Pennsylvania16 studies
- Tennessee13 studies
- Texas26 studies
- Utah7 studies
- Virginia8 studies
- Washington10 studies
- Wisconsin10 studies
Recently updated studies
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07439653Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06052826A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06213311A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05615636A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Sep 16, 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RecruitingPhase 1/2
31 Days – 30 Years · All sexes · Updated Sep 14, 2026 · NCT04544592Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06634589Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT05272384Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06393738Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 3, 2026 · NCT07652580Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07516093A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07123454Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07520006A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07220616Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT04792502A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.